Sun Pharma
Manufacturing · India · 10K+ Employees
View Company Info for Free
Overview
Headquarters
Sun House cts no. 201 b/1 Western Expres...Phone Number
+91 2243244324Website
www.sunpharma.comRevenue
$6.2 BillionStock Symbol
SUNPHARMAIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
13
14
1
2
2
2
About Sun Pharma
Sun Pharma is a specialty generic pharmaceutical company that manufactures and distributes pharmaceutical formulations and active pharmaceutical ingredients. It is heaquartered in Mumbia, India.Explore more
Sun Pharma Org Chart
KG
Regional Financial Controller
AG
Plant Finance Controller
DP
Controller
AK
API Controller
KB
Manager - Plant Financial Controller
BG
Senior Credit Controller
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sun Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Sun Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Sun Pharma had a recent Job posting/layoffs
Check out if Sun Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Sun Pharma has new funding data
Earning: See what the market has to say on Sun Pharma recently announced quarterly report
Product Launch: Get notified when Sun Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Sun Pharma
Check if Sun Pharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Sun Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to Sun Pharma
Compare insights from companies similar to Sun Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$17.3B
10K+
Public
$99.3B
1901
NB
Nishank BhargavaRegional Director, Finance & Chief Financial Officer (India)
Company Profile Activity
Activity Insights
Sun Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sun Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sun Pharma.
Sun Pharma Tech Stack
A closer look at the technologies used by Sun Pharma
Most Recent Scoops
Earnings
Sun Pharma has reported volume growth of 6% for Q4 FY26, surpassing the Indian Pharmaceutical Market volume growth of 1.6%, and continues to rank number one by prescription volumes across 11 different doctor categories as per the SMSRC November–February 2026 report.
Doctors / Physicians, Pharmaceuticals
Project
Sun Pharma has announced that the FDA accepted the review of the Biologics License Application (BLA) for ILUMYA for the treatment of adults with active psoriatic arthritis, with a regulatory action date set for late October 2026.
Pharmaceuticals
Facilities Relocation / Expansion
Sun Pharma is establishing a new greenfield sterile-only manufacturing facility in Madhya Pradesh, India, designed to support future supply capacity requirements across major global geographies, including US generics, as the company's production volumes continue to expand.
Facilities Relocation/Expansion, Capacity Planning, Pharmaceuticals, Manufacturing Operations
Earnings
Sun Pharma has reported sales of INR 145,598 million for Q4 FY26, reflecting a year-over-year growth of 13.6%. EBITDA for the quarter was INR 39,542 million, an increase of 6.4% over Q4 FY25, with an EBITDA margin of 27.1%, compared to 28.7% in Q4 FY25 and 31.9% in Q3 FY26. Gross margin for the quarter was 80.8%, higher than the same period last year, largely driven by a better product mix.
Earnings, Finance
Product Launch
Product Launch
Sun Pharma News & Media
At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)
Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients MUMBAI, India and...Sun Pharma signs Definitive Agreement to Acquire Organon | Business Wire - Via TT
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia.Sun Pharma shares rise 9% after $11.75B Organon acquisition confirmed
India’s Sun Pharmaceutical Industries and Organon & Co today announced a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $ 1.75 billion.Sun Pharma to acquire Organon for $11.75bn
Following the transaction’s completion, Sun Pharma will have a combined revenue of $12.4bn.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Sun Pharma
Sign Up For FreeTo access detailed company insights
Sun Pharma is a specialty generic pharmaceutical company that manufactures and distributes pharmaceutical formulations and active pharmaceutical ingredients. It is heaquartered in Mumbia, India.... Read More
